使用强力多巴胺和血清素激动剂利舒脲治疗进行性核上性麻痹。
The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.
作者信息
Neophytides A, Lieberman A N, Goldstein M, Gopinathan G, Leibowitz M, Bock J, Walker R
出版信息
J Neurol Neurosurg Psychiatry. 1982 Mar;45(3):261-3. doi: 10.1136/jnnp.45.3.261.
Seven patients with progressive supranuclear palsy were treated with lisuride. Mean age was 62 years (range, 52 to 68 years), and duration of disease was 4.4 years (range, 1 to 7 years). All seven had been treated with levodopa/carbidopa and three with bromocriptine; four had, at one time, shown a partial response to levodopa. One patient had also shown a partial response to bromocriptine. Lisuride was used alone in four patients, and combined with levodopa/carbidopa in three patients. Mean dose of lisuride was 2.5 mg (range, 1.5 to 5.0 mg). Mean duration of treatment was 4 months (range, 1 to 10 months). While two patients showed a reduction in rigidity, one in tremor and two in bradykinesia, in only one of them was there an overall improvement. It is postulated that the relative lack of response to lisuride may be due to a loss of both the dopaminergic and serotonergic receptors in progressive supranuclear palsy.
七名进行性核上性麻痹患者接受了利苏力特治疗。平均年龄为62岁（范围为52至68岁），病程为4.4年（范围为1至7年）。所有七名患者均接受过左旋多巴/卡比多巴治疗，三名患者接受过溴隐亭治疗；四名患者曾对左旋多巴有部分反应。一名患者也曾对溴隐亭有部分反应。四名患者单独使用利苏力特，三名患者将其与左旋多巴/卡比多巴联合使用。利苏力特的平均剂量为2.5毫克（范围为1.5至5.0毫克）。平均治疗持续时间为4个月（范围为1至10个月）。虽然两名患者的强直有所减轻，一名患者的震颤有所减轻，两名患者的运动迟缓有所减轻，但只有一名患者有整体改善。据推测，对利苏力特反应相对不足可能是由于进行性核上性麻痹中多巴胺能和5-羟色胺能受体均丧失所致。
Zotero 插件